Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer s, results of a phase 3 trial show.
Recruitment begins in early Alzheimer s Phase 2 Elayta trial alzheimersnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzheimersnewstoday.com Daily Mail and Mail on Sunday newspapers.
FDA converts novel Alzheimer s disease treatment to traditional approval highlandcountypress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from highlandcountypress.com Daily Mail and Mail on Sunday newspapers.
FDA approved Eisai s Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer s Disease. Find out why ESALF stock is a Buy.
The FDA converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.